Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2014

View Archived Issues

A*STAR partners with Roche in cancer

Merck & Co. patents novel HIV integrase inhibitors

Actelion presents novel P2X7 receptor antagonists

Grant supports DiamiR's work on brain-enriched microRNA biomarkers for Parkinson's disease

Ratiopharm claims new MMF prodrugs

Almirall patents novel dual beta2 agonists and M3 antagonists

Serum peptide signature detects early-stage lung cancer

Gene signature correlated with prognosis in colorectal cancer

Novel agents for cancer and infections reported by the University of Washington

Purdue Pharma patents new Na(v)1.7 channel blockers

C4T discloses new cannabinoid CB2 receptor agonists

Takeda Pharmaceutical discloses novel DAAO inhibitors

Ventrus Biosciences becomes Assembly Biosciences

PharmaMar and Chugai enter into license agreement in Europe for Aplidin

Treatment with PF-05231023 improves lipid parameters in patients with type 2 diabetes

ZS Pharma completes enrollment in second phase III study of ZS-9 in hyperkalemia

Abbott to sell part of generics business to Mylan

AstraZeneca's proton pump inhibitor enters pediatric phase I/II clinical trial

BioChaperone Combo shows promising PK/PD profile in early clinical trials

Novartis collaborates with Banner Alzheimer's Institute on AD prevention study

SBIR grant supports Cel-Sci's development of LEAPS technology for RA

Neos Therapeutics reports phase III findings for NT-0102

FDA grants priority review to sNDA for simeprevir in combination with sofosbuvir

GSK and Theravance initiate phase III program of triple combination treatment for COPD

Nymox completes enrollment in second re-injection study of NX-1207 for BPH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...